Post-Authorisation Safety Study (PASS) of CLAIRYG® (Human normal immunoglobulin for intravenous use) in children under 12 years treated for primary immunodeficiency (PID) or immune thrombocytopenic purpura (ITP) (IGNGPASSP)First published 22/05/2020 Last updated 23/04/2024 EU PAS number: EUPAS33320StudyFinalised